Crystal engineering of cystic fibrosis drug ivacaftor: Salts, solvates, and hydrate forms with solubility and stability studies | Synapse
February 2, 2026
Crystal engineering of cystic fibrosis drug ivacaftor: Salts, solvates, and hydrate forms with solubility and stability studies
Key Points
The central aim is to enhance the solubility and stability of ivacaftor through various crystal forms.
Utilized crystal engineering techniques to create salts, solvates, and hydrates of ivacaftor.
Conducted solubility and stability studies on different crystal forms.
Analyzed the impact of various formulations on the drug's properties.
Identified specific crystalline forms of ivacaftor with improved solubility characteristics.
Demonstrated that certain hydrates enhance stability compared to the parent compound.
Achieved a marked increase in the drug's performance as a cystic fibrosis treatment.
Abstract
Ivacaftor (IVA) is a selective small-molecule potentiator used to treat cystic fibrosis in patients with certain genetic mutations. It is a BCS class II drug having poor aqueous solubility. The...